FDA rejected Disc Medicine's rare blood disease candidate despite expedited priority-voucher review, blocking its immediate approval pathway.
Longevity News
The FDA has rejected a rare blood disease candidate from Disc Medicine, a compound that been granted expedited review...
Source: FierceBiotech - Biotech • Published: 19 Feb 2026, 22:00
Continue exploring
Related longevity signals
Longevity TechnologyNRG Therapeutics shows promising lab results for new ALS drug candidateNRG Therapeutics’ preclinical report invites readers to examine lab and mechanistic data for a novel ALS drug candidate and its next-stage plans.Frontiers - HealthTelitacicept in myasthenia gravis: a systematic review of clinical outcomes, steroid-sparing effects, and safetyA systematic review synthesizes clinical evidence on a B-cell–targeting biologic for myasthenia gravis, focusing on outcomes, steroid reduction, and safety.TechCrunchMichael Polansky is training an AI model on skin that’s still aliveReport on a startup combining living human skin tissue maintenance with AI to accelerate discovery of new topical cosmetic compounds and testing workflows.Frontiers - HealthThe Bidirectional Relationship between Epilepsy and Sleep: A Narrative ReviewReview synthesizing neurophysiological links, clinical interactions, and management strategies between sleep disorders and epilepsy.